Table 1.

ACR20 rates for ustekinumab in phase III studies

	PSUMMIT-1				PSUMMIT-2
	Week 12*	Week 24			Week 24
	ACR20	ACR20	ACR50	ACR70	ACR20	ACR50	ACR70	ACR20 (TNFIR)
Placebo	21	23	9	2	23	7	3	15
UST45 mg	41	42	25	12	44	18	7	37
UST90 mg	41	50	28	14	44	23	9	35

All figures are (rounded) percentages

ACR American College of Rheumatology

* Taken from figure 2A in McInnes et al. [47]